From: Early severe morbidity and resource utilization in South African adults on antiretroviral therapy
Variable | HAART | No-HAART | p-value |
---|---|---|---|
Number of Admissions | |||
Total admissions | 70 | 60 | |
First admissions | 53 | 53 | |
Median Age | 32 (IQR 29-35) | 32 (IQR 27-40) | p = 0.871 |
Gender | p = 0.647 | ||
Men | 20 (29%) | 15 (25%) | |
Women | 50 (71%) | 45 (75%) | |
Referral source | p = 0.000 | ||
public primary-care clinic | 52 (74%) | 29 (48%) | |
secondary hospital clinic | 10 (14%) | 2 (3%) | |
tertiary hospital clinic | 3 (4%) | 0 | |
private medical doctor | 4 (6%) | 16 (27%) | |
not recorded | 1 (1%) | 13 (22%) | |
Prior WHO Stage | p = 0.040 | ||
Stage I | 0 (0%) | 3 (5%) | |
Stage II | 0 (0%) | 0 (0%) | |
Stage III* | 13 (19%) | 18 (30%) | |
Stage IV* | 57 (81%) | 39 (65%) | |
CD4 Count × 106 cells/L | |||
Number performed | 64 (91%) | 11 (18%) | |
Median CD4 count | 57 (IQR 15-115) | 16 (IQR 10-316) | p = 0.96 |
Cotrimoxazole prophylaxis | 36 | 7 | p = < 0.001 |